Currently, in the EU, around 60% of the consumed protein is animal-based, which production and consumption leads to (i) scarcity of land available for other uses, such as crop production; (ii) health risks, such as type 2 diabetes or colon cancer, diseases associated to red and processed meats consumption; (iii) increasing negative environmental impact and GHG emissions; and (iv) growing EU dependence of protein imports from outside the EU, especially from South America, where it is leading to deforestation and land pressure.
Quinoa, an herbaceous plant that has been traditionally grown in South America for over 5,000 years, has recently raised a global interest and has been recognised by the FAO as a valuable crop for enhancing food security due to the high nutritional density of the seeds. Protein content in quinoa is higher compared to common cereals (rice, maize, rye, etc.), and unlike most plants, it contains all essential amino acids in the right amounts for the human body.
With our innovative QUINNOVA process, an innovative fractionation method for valorising EU cultivated low saponin quinoa seeds, we aim to produce two valuable ingredients demanded by the market place: Protein-Rich Quinoa to replace protein ingredients from animal sources and gluten-free Quinoa Starch, highly valuable for formulating high-quality gluten-free products.
The ultimate aim of the QUINNOVA project is to validate the current technology and up-scale its production process in order to scale up both QUINNOVA products into the market.